# Kiruthika Ganesan
## Pharmaceutical Scientist | Process Consultant | Analytical Innovation Specialist

> Bridging pharmaceutical science and business impact through data-driven problem-solving

[![Email](https://img.shields.io/badge/Email-kiruthiganesan2020@gmail.com-red)](mailto:kiruthiganesan2020@gmail.com)
[![LinkedIn](https://img.shields.io/badge/LinkedIn-Connect-blue)](https://linkedin.com/in/yourprofile)

---

## ğŸ‘‹ About Me

B.Pharm graduate specializing in **pharmaceutical process optimization** and **analytical method development** with proven ability to translate complex technical challenges into measurable business outcomes.

**What I Do:**
- Apply consulting frameworks (root-cause analysis, ROI modeling) to pharmaceutical manufacturing and R&D challenges
- Develop innovative analytical methods that improve regulatory compliance and reduce costs
- Translate scientific complexity into clear business recommendations for stakeholders

**Current Focus:**
- ğŸ† Competing in **Novartis NEST 2.0 Innovation Challenge** (Analytical Method Development)
- ğŸ”¬ Advancing expertise in pharmaceutical quality systems and CMC strategy
- ğŸ’¼ Exploring pharmaceutical consulting opportunities in process optimization and regulatory affairs

---

## ğŸ¯ Featured Projects

### ğŸ† [Hybrid Mass Balance Model for Forced Degradation Studies](./NEST-Mass-Balance-Project.md)
**Novartis NEST 2.0 Innovation Challenge | Solo Researcher**

**The Problem:** Mass balance calculations in pharmaceutical stability studies frequently fall outside regulatory acceptance criteria (95-105%), delaying drug approvals and costing companies millions in submission delays.

**My Solution:** Developed a hybrid analytical-mathematical model integrating response factor correction, internal standard normalization, and peak purity adjustment.

**Expected Impact:**
- âœ… **40% improvement** in mass balance accuracy
- âœ… Target consistency: **98-102%** (vs. current 92-105% variance)
- âœ… **Reproducible methodology** for regulatory submissions
- âœ… **Applicable industry-wide** across all pharmaceutical stability workflows

**Skills Demonstrated:** Analytical method validation, statistical modeling, regulatory science, independent research execution

**Status:** Round 1 submission complete | Advancing to mentorship phase

---

### ğŸ’¼ [Tablet Manufacturing Process Optimization](./Process-Optimization-Case-Study.md)
**Process Consulting Project | 3 Weeks**

**The Business Challenge:** Standard tablet manufacturing line experiencing 26-hour cycle times, 6% rejection rates, and manual documentation creating compliance risks.

**My Approach:** Applied management consulting frameworks (Ishikawa diagrams, 5-Why analysis) to identify three critical bottlenecks: excessive drying time, compression weight variation, and documentation delays.

**Business Impact:**
- âš¡ **12% reduction in cycle time** (26h â†’ 22.9h)
- ğŸ’° **â‚¹5 lakh annual cost savings** (reduced rework + increased capacity)
- ğŸ“ˆ **4-point improvement in first-pass yield** (94% â†’ 98%)
- ğŸ’µ **<2-month ROI** on recommended equipment investment

**Deliverables:** Executive summary deck, ROI financial model, implementation roadmap with risk mitigation

**Why This Matters:** Demonstrates ability to apply structured business problem-solving to pharmaceutical operationsâ€”exactly what consulting firms deliver to manufacturing clients.

---

## ğŸ’¼ Consulting-Style Case Work

### Process Optimization & Root-Cause Analysis
Expert in applying structured frameworks to diagnose and solve pharmaceutical manufacturing inefficiencies:
- Ishikawa (fishbone) diagrams for systematic cause mapping
- 5-Why methodology for root-cause identification
- Time-motion analysis and process flow mapping
- ROI modeling and cost-benefit analysis

### Analytical Method Development & Validation
Specialized in developing regulatory-compliant analytical methods that reduce submission risk:
- HPLC/UPLC method development for stability studies
- Mass balance calculations with statistical rigor
- Forced degradation protocol design (ICH Q1A/Q1B)
- Response factor validation and internal standard optimization

### Regulatory & Quality Systems
Understanding of pharmaceutical compliance requirements and quality frameworks:
- ICH guidelines (Q1A, Q1B, Q2, Q3)
- FDA/CDSCO regulatory pathways
- Data integrity and documentation best practices
- Risk-based approach to method validation

---

## ğŸ“„ Scientific Writing & Research

### [Instrumental Approaches in Neuropharmacological Screening](./Neuropharm-Screening-Review.pdf)

**Business Context:** Preclinical drug screening costs pharmaceutical companies $800M-$2.6B per approved drug. Accurate early-stage testing reduces expensive late-stage failures.

**My Contribution:** Comprehensive review of instrumental methods (Electroconvulsiometer, Actophotometer) for efficient CNS drug evaluation, providing standardized protocols for regulatory-ready screening.

**Commercial Impact:** Enables faster, more objective preclinical assessment, reducing R&D waste and improving reproducibility across labsâ€”critical for regulatory submissions.

**Key Insight:** Standardized instrumental methods improve cross-lab comparisons and reduce variability in drug candidate selection.

ğŸ“¥ [Download Full Review (PDF)](./Instrumental+Approaches+in+Neuropharmacological+Screening+A+Review+of+Insights+from+Electroconvulsiometer+and+Actophotometer+Studies.pdf)

---

### [Dostarlimab: Breakthrough Immunotherapy in Endometrial Cancer](./Dostarlimab-Review.md)

**Business Context:** Oncology immunotherapies represent a $150B+ global market with breakthrough therapies commanding premium pricing and market access.

**My Analysis:** Reviewed dostarlimab's mechanism (PD-1 monoclonal antibody), clinical trial breakthroughs, and competitive positioning in dMMR/MSI-H cancers.

**Market Relevance:** High remission rates with fewer severe adverse effects create compelling value proposition for payers and positioning advantage vs. existing immunotherapies.

**Consulting Angle:** Understanding drug development pipelines, clinical differentiation, and commercial positioning is essential for pharma strategy consulting.

---

### [Spinal Muscular Atrophy: Molecular Therapies & Nutritional Management](./SMA_Poster.pdf)

**Clinical Context:** SMA affects 1 in 10,000 births. Recent molecular therapies (Spinraza, Zolgensma) transformed it from fatal to treatable but require comprehensive care strategies.

**My Focus:** Analyzed multidisciplinary treatment approaches including gene therapy, antisense oligonucleotides, and critical nutritional support for swallowing/metabolic challenges.

**Healthcare Economics:** Understanding rare disease treatment landscapes, specialized care requirements, and patient journey mappingâ€”relevant to pharma commercial strategy and patient access programs.

ğŸ“¥ [View Research Poster (PDF)](./SMA_Poster.pdf)

---

### [Novel Spinraza Formulation Using Graphene Quantum Dots](./Spinal_muscular_atrophy_(1).doc)

**Innovation Context:** Spinraza requires frequent intrathecal injections ($125K per dose), creating patient burden and access challenges.

**My Proposal:** Explored GQD-based formulation to improve cellular uptake, bioavailability, and reduce injection frequencyâ€”addressing major treatment limitations.

**R&D Strategy Insight:** Nanotechnology applications in reformulation can extend drug lifecycle, improve patient compliance, and create competitive differentiation.

ğŸ“¥ [View Technical Document](./Spinal_muscular_atrophy_(1).doc)

---

### [Sitophilus oryzae: IPM Strategies for Stored-Grain Pest Management](./Rice-Weevil-Review.md)

**Agricultural Economics:** Post-harvest grain losses cost developing economies billions annually. The rice weevil causes significant quality degradation and storage losses.

**My Analysis:** Reviewed sustainable integrated pest management (IPM) approaches including botanicals, biocontrol, and molecular tools as alternatives to chemical pesticides.

**Market Opportunity:** Growing demand for pesticide-free food products creates commercial opportunity for biological control solutions.

**Cross-Industry Application:** Demonstrates ability to analyze complex problems in adjacent sectors (agriculture/food safety) using evidence-based approaches.

---

## ğŸ› ï¸ Technical & Business Skills

### Pharmaceutical Expertise
- **Analytical Techniques:** HPLC/UPLC, dissolution testing, stability studies
- **Formulation Development:** Tablet manufacturing (granulation, compression, coating), excipient optimization
- **Quality Systems:** Deviation management, CAPA, method validation, data integrity
- **Regulatory Knowledge:** ICH guidelines, FDA/CDSCO requirements, stability testing protocols

### Business & Consulting Skills
- **Problem-Solving Frameworks:** Root-cause analysis (Ishikawa, 5-Why), process mapping, bottleneck identification
- **Financial Analysis:** ROI modeling, cost-benefit analysis, payback period calculations
- **Stakeholder Management:** Cross-functional collaboration, presenting to technical and non-technical audiences
- **Project Management:** Independent project execution, timeline management, deliverable creation

### Software & Tools
- **Data Analysis:** Microsoft Excel (advanced: pivot tables, financial modeling), Minitab (statistical analysis), basic Python
- **Documentation:** MS Office Suite (Word, PowerPoint, Visio), technical writing, executive summaries
- **Chromatography Software:** Empower, ChemStation (or equivalent based on your experience)
- **Visualization:** Creating process maps, dashboards, and client-ready presentations

---

## ğŸ“ Education & Achievements

**Bachelor of Pharmacy (B.Pharm)**  
*[JKK MUNIRAJAH INSTITUTE OF HEALTH SCIENCES,COLLEGE OF PHARMACY]*  
*Graduated: [2026]*

**Key Academic Projects:**
- Forced degradation studies and analytical method development
- Formulation optimization for modified-release tablets
- Quality control and regulatory documentation

**Competitions & Recognition:**
- ğŸ† **Novartis NEST 2.0 Innovation Challenge** - Selected for Round 1 advancement
- ğŸ“Š Process optimization project recognized for business impact potential

---

## ğŸ’¡ What Makes Me Different

**I don't just understand pharmaceutical scienceâ€”I understand pharmaceutical business.**

Most pharmacy graduates can run an HPLC or formulate a tablet. I can do that *and*:
- Calculate the ROI of a process improvement
- Identify bottlenecks using consulting frameworks
- Present technical recommendations to non-technical stakeholders
- Frame analytical problems in terms of business impact

This combination of **technical depth + business thinking** is exactly what pharmaceutical consulting firms need when advising clients on manufacturing optimization, quality systems, and regulatory strategy.

---

## ğŸ“« Let's Connect

I'm interested in opportunities at the intersection of pharmaceutical science and business strategy, particularly:
- **Pharmaceutical consulting** (process optimization, CMC, quality systems)
- **Analytical R&D roles** with business impact focus
- **Regulatory affairs** (CMC submissions, method validation)
- **Scientific communication** (translating complexity for stakeholders)

**Get in touch:**
- ğŸ“§ Email: [kiruthiganesan2020@gmail.com](mailto:kiruthiganesan2020@gmail.com)
- ğŸ’¼ LinkedIn: [Connect with me](https://linkedin.com/in/yourprofile)
- ğŸ“„ Portfolio: [View detailed case studies](https://yourportfoliosite.com)

---

## ğŸŒŸ Featured Skills Summary

```
Technical Expertise          Business Acumen              Consulting Skills
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€           â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
âœ“ HPLC/LC-MS                âœ“ ROI Analysis               âœ“ Root-Cause Analysis
âœ“ Method Validation         âœ“ Cost-Benefit Modeling      âœ“ Process Mapping  
âœ“ Stability Testing         âœ“ Process Optimization       âœ“ Stakeholder Mgmt
âœ“ Formulation Dev           âœ“ KPI Development            âœ“ Executive Comms
âœ“ Regulatory Science        âœ“ Business Case Writing      âœ“ Problem Structuring
```

---

## ğŸ“Š By The Numbers

- **12%** cycle time reduction in manufacturing optimization project
- **40%** expected improvement in mass balance accuracy (NEST project)
- **â‚¹5L** annual cost savings identified through process analysis
- **<2 months** ROI on recommended process improvements
- **5+** comprehensive scientific reviews published/presented

---

## ğŸ“š Additional Research & Writing

Want to see more? I've written extensively on pharmaceutical topics ranging from neuropharmacology to biotechnology innovations. Each piece demonstrates my ability to:
- Synthesize complex scientific literature
- Identify practical applications and business implications
- Communicate technical concepts clearly
- Connect academic research to commercial opportunities

*All publications available in this repository with business context annotations.*

---

## ğŸš€ Current Status

**Actively seeking:**
- Full-time roles in pharmaceutical consulting, quality/CMC, or analytical R&D
- Internship opportunities at consulting firms (ZS Associates, IQVIA, L.E.K., specialty pharma consultancies)
- Collaborative projects bridging pharmaceutical science and business strategy

**Immediate availability:** [Your timeline]

---

<div align="center">

### "Translating pharmaceutical complexity into business impactâ€”one project at a time."

**â­ If you found this portfolio valuable, consider connecting on LinkedIn or reaching out for collaboration opportunities!**

</div>

---

*Last Updated: December 2024*
